Regenxbio (RGNX) Q4 2025 earnings summary

Executive summary

• 2026 is a pivotal year with late-stage pipeline advancements and commercial readiness in Duchenne muscular dystrophy (DMD), wet AMD, and diabetic retinopathy, supported by key collaborations with AbbVie and Nippon Shinyaku.

• RGX-202 for DMD completed pivotal trial dosing in 2025, with robust enrollment and strong safety and efficacy, especially in older patients; pivotal topline results expected early Q2 2026.

• RGX-314/Sura-vec for wet AMD and diabetic retinopathy is advancing, with pivotal data expected Q4 2026 and first patient dosing in the NAVIGATE/NAAVIGATE trial anticipated in Q2 2026; $100M milestone from AbbVie expected upon dosing.

• MPS programs (RGX-111, RGX-121) faced clinical holds and a recent CRL due to safety concerns, with management addressing regulatory requirements and committed to resubmission.

Financial highlights

• Cash, cash equivalents, and marketable securities were $241M at year-end 2025, down slightly from $245M in 2024.

• 2025 revenue totaled $170.4M, up from $83.3M in 2024, driven by Nippon Shinyaku collaboration and increased royalties.

• R&D expenses rose to $228.3M in 2025 from $208.5M in 2024, mainly due to pivotal trial execution and manufacturing.

• Net loss for 2025 was $193.9M ($3.76 per share), an improvement from $227.1M ($4.59 per share) in 2024.

• Cash runway is expected to fund operations into early 2027, excluding potential $100M milestone from AbbVie and additional royalty monetization proceeds.

Outlook and guidance

• Top-line pivotal data for RGX-202 in DMD expected early Q2 2026, with BLA submission planned following FDA engagement mid-year.

• RGX-314/Sura-vec pivotal data for wet AMD anticipated in Q4 2026; NAVIGATE/NAAVIGATE trial in diabetic retinopathy to dose first patient in Q2 2026.

• Cash runway could extend into the second half of 2027 with anticipated milestones and royalty proceeds.